stockportfolio.pro
Alto Neuroscience, Inc. (ANRO)
Healthcare · Biotechnology · NYSE
Alto Neuroscience, Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — |
| Net income | $-27.71M | $-36.30M | $-61.43M | $-63.24M |
| Net margin | — | — | — | — |
Source: Alto Neuroscience, Inc. SEC filings (10-K).
Explore 4 years of Alto Neuroscience, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ANRO in your portfolio →
Alto Neuroscience, Inc. financial history by metric
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Alto Neuroscience, Inc. — frequently asked questions
What is Alto Neuroscience, Inc.'s revenue?
Alto Neuroscience, Inc. (ANRO) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Alto Neuroscience, Inc. profitable?
No — ANRO reported a net loss of $-63.24M in fiscal 2025.
What is ANRO's P/E ratio?
Alto Neuroscience, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Alto Neuroscience, Inc. have?
As of fiscal year 2025, ANRO carried roughly $18.98M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Alto Neuroscience, Inc.'s market cap?
Alto Neuroscience, Inc. (ANRO) has a market capitalization of about $726.09M, based on the latest data in our nightly-refreshed cache.
When does Alto Neuroscience, Inc.'s fiscal year end?
ANRO's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Alto Neuroscience, Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.